Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity
Open accessPublished version of a preprint
The DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.
Abstract
Purpose: Irinotecan (CPT-11) induced diarrhea occurs frequently in patients with cancer and limits its usage. Bacteria β-glucuronidase (GUS) enzymes in intestines convert the nontoxic metabolite of CPT-11, SN-38G, to toxic SN-38, and finally lead to damage of intestinal epithelial cells and diarrhea. We previously reported amoxapine as a potent GUS inhibitor in vitro. To further understand the molecular mechanism of amoxapine and its potential for treatment of CPT-11–induced diarrhea, we studied the binding modes of amoxapine and its metabolites by docking and molecular dynamics simulation, and tested the in vivo efficacy on mice in combination with CPT-11. Experimental Design: The binding of amoxapine, its metabolites, 7-hydroxyamoxapine and 8-hydroxyamoxapine, and a control drug loxapine with GUS was explored by computational protocols. The in vitro potencies of metabolites were measured by Escherichia coli GUS enzyme and cell-based assay. Low-dosage daily oral administration was designed to use along with CPT-11 to treat tumor-bearing mice. Results: Computational modeling results indicated that amoxapine and its metabolites bound in the active site of GUS and satisfied critical pharmacophore features: aromatic features near bacterial loop residue F365′ and hydrogen bond toward E413. Amoxapine and its metabolites were demonstrated as potent in vitro. Administration of low dosages of amoxapine with CPT-11 in mice achieved significant suppression of diarrhea and reduced tumor growth. Conclusions: Amoxapine has great clinical potential to be rapidly translated to human subjects for irinotecan-induced diarrhea. Clin Cancer Res; 20(13); 3521–30. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methimazole (CYP3A inhibitor) [108], neomycin (β-glucuronidase inhibitor) [109] and amoxapine (β-glucuronidase inhibitor) [110] have been shown to reduce SN-38 degradation effectively.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239 · cited 1×
“All covalent bonds to hydrogen atoms were constrained using the SHAKE algorithm (24).”
MethodDevelopment and testing of a general amber force field
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20035 · Cited by 19,506
Comparison of multiple Amber force fields and development of improved protein backbone parameters
Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21123 · Cited by 6,914 · cited 1×
“The Amber ff99SB force field (21) and general Amber force field (GAFF; ref.”
BackgroundDose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“243 mg/kg human equivalent dose (HED), respectively (32).”
BackgroundKollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., et al. (2000) · Accounts of Chemical Research · doi:10.1021/ar000033j · Cited by 4,978
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365 · cited 1×
“production, and the processing of bile acids, sterols, and xenobiotics; they are not optimal for the patients already challenged by tumor growth and chemotherapy (34, 35).”
BackgroundHou, T., Wang, J., Li, Y., & Wang, W. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100275a · Cited by 2,773
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277 · cited 1×
“Irinotecan (CPT-11) is a commonly used chemotherapeutic agent for the treatment of malignances, such as cancers of brain, colon, and lung, and refractory forms of leukemia and lymphoma (1).”
BackgroundAlleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080 · cited 10×
“Clin Cancer Res; 20(13) July 1, 2014 Clinical Cancer Research 3522”
BackgroundMethodInfluentialSelf-citation
Cited by
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
Carbohydrate-active enzymes (CAZymes) in the gut microbiome
Wardman, J. F., Bains, R. K., Rahfeld, P., & Withers, S. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00712-1 · Cited by 597
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“In addition, b-glucuronidase activity has been correlated to intestinal damage and diarrhea in rats/mice, which could (potentially) be reduced by inhibiting b-glucuronidase with antibiotics (penicillin and streptomycin) or amopaxine [56, 57].”
Background
Metadata
- Authors
- Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C.
- Affiliations
- Houston Methodist Research Institute (US)
- North Carolina Central University (US)
- Houston Methodist (US)
- Corresponding author
- Zhao, Hong
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2014-06-30
- Volume
- 20
- Issue
- 13
- Pages
- 3521-3530
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4079752
- OpenAlex
- W2097468619
- Cited by
- 90
- References
- 46
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 9 · 2022: 8 · 2021: 17 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 8 · 2016: 3 · 2015: 3
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Houston Methodist Research Institute
- National Cancer Institute (U54CA156735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- amoxapine, irinotecan, β-glucuronidase inhibition, SN-38 glucuronidation, drug repurposing, drug metabolites, Escherichia coli, intestinal toxicity, pharmacophore modeling, drug combination therapy
- MeSH terms
- Irinotecan, Amoxapine, Animals, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Camptothecin, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme Activation, Female, Glycoproteins, Molecular Conformation, Neoplasms, Protein Binding, Protective Agents, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Molecular Dynamics Simulation, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0395
- The paper
- Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014). Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.